European Archives - Page 215 of 1449 - European Medical Journal

AI Tool Calculates Biological Age for Early Disease Detection

AI model integrating health outcomes offers more accurate biological age estimates, helping clinicians identify disease risk earlier.

Transthyretin Cardiac Amyloidosis: A Major Cause of Heart Failure in Older Black Men

Undiagnosed heart condition affects up to one in six older Black men with heart failure, new research finds.

TMOD2 Identified as Key Driver of Liver Metastasis in Colorectal Cancer

Researchers have uncovered a central role for Tropomodulin-2 (TMOD2) in promoting colorectal cancer (CRC) progression and liver metastasis.

First Clinical Signals of Post-Therapy HIV Control Emerge

A landmark trial combining novel therapies has produced the first signs of durable post-treatment HIV control, pointing to a new frontier in functional cure research.

18 Sep 2025

COPD Has Many Faces

Case study of a 59-year-old COPD patient with emphysema, showing disease presentation, progression, exacerbation, and improved outcomes after tailored treatment.

Person typing on computer

New study reveals risks of patients using ChatGPT

Patients are increasingly turning to ChatGPT for medical advice, but new research warns it isn’t yet accurate enough to be relied on alone.

EADV 2025: Sleep Apnoea Linked to Increased Skin Disorders

Beyond disease associations, CPAP mask-related skin complications such as dermatitis may arise due to friction, pressure, moisture, or sensitivity to mask materials.

Respiratory Care in a Changing Climate

This expert-led podcast explores healthcare sustainability in the face of climate change, highlighting how guideline-directed…

EADV 2025: Delays in AD Treatment Differ Across UK

A key finding was that patients treated at specialist centres experienced a significantly shorter delay in switching from immunosuppressants to advanced systemic therapies.

Biparametric MRI Matches Multiparametric Accuracy in Prostate Cancer

Results showed that bpMRI was noninferior to mpMRI for detecting clinically significant prostate cancer, defined as Gleason Grade Group 2 or higher.